RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/a-2444-3438
Sinonasal Plasmablastic Lymphoma: A Systematic Review
Funding None.
Abstract
Objective Plasmablastic lymphoma (PBL) is a type of non-Hodgkin's B-cell lymphoma associated with human immunodeficiency virus and Epstein–Barr virus, commonly located in the oral cavity or gastrointestinal tract. Sinonasal involvement is rare, and there is no consensus on treatment.
Data Sources Peer-reviewed published articles served as data sources.
Review Methods A systematic review was conducted of the PubMed database for all cases of sinonasal PBL between 1978 and 2023 with the phrase “plasmablastic lymphoma.” Studies not written in English and that did not separate individual cases of sinonasal PBL from aggregated data were excluded. Age, sex, immune status, treatment, and outcomes were collected.
Conclusion PBL is a rare malignancy in the sinonasal region usually treated with chemotherapy. It most commonly occurs in immunocompromised adults but has also been diagnosed in immunocompromised children and in immunocompetent adults. It is aggressive and has a poor prognosis.
Implications for Practice PBL is a recently described entity with few cases of the sinonasal anatomic variant in the literature. Sinonasal PBL was most frequently treated with chemotherapy alone, closely followed by chemoradiation. The most common chemotherapy regimen utilized in the literature is cyclophosphamide, doxorubicin, oncovin/vincristine, and prednisone, which is also the most common chemotherapy regimen in nonsinonasal PBL. A second commonly used regimen is cyclophosphamide, vincristine/oncovin, doxorubicin/adriamycin, and dexamethasone. However, no treatment has emerged as superior to others with regard to survival. Further data are needed to better understand this rare disease.
Keywords
plasmablastic lymphoma - sinonasal lymphoma - non-Hodgkin's lymphoma - diffuse large B-cell lymphoma - sinonasal neoplasmAuthors' Contributions
S.C. contributed to study design, data acquisition and interpretation, and manuscript writing; H.C. was involved in data acquisition and interpretation as well as manuscript writing; S.S. participated in data acquisition and interpretation along with manuscript writing; and M.W. contributed to study design, data acquisition and interpretation, and manuscript writing.
Previous Presentation
This article was presented at the AAO-HNSF 2023 Annual Meeting & OTO Experience, Nashville, Tennessee, September 30–October 4, 2023.
Publikationsverlauf
Eingereicht: 01. September 2024
Angenommen: 08. Oktober 2024
Artikel online veröffentlicht:
13. November 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Delecluse HJ, Anagnostopoulos I, Dallenbach F. et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89 (04) 1413-1420
- 2 Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ. Plasmablastic lymphoma: An update. Int J Lab Hematol 2022; 44 (Suppl 1, Suppl 1): 54-63
- 3 Colomo L, Loong F, Rives S. et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28 (06) 736-747
- 4 Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015; 125 (15) 2323-2330
- 5 Swerdlow SH, Campo E, Harris NL. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol 2: International agency for research on cancer Lyon, France; 2008
- 6 Vaughan J, Perner Y, Mayne E, Wiggill T. Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use. HIV Med 2021; 22 (03) 225-230
- 7 Morscio J, Dierickx D, Nijs J. et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38 (07) 875-886
- 8 Pather S, MacKinnon D, Padayachee RS. Plasmablastic lymphoma in pediatric patients: clinicopathologic study of three cases. Ann Diagn Pathol 2013; 17 (01) 80-84
- 9 Goedhals J, Stones DK, Botha MC. Plasmablastic lymphoma in childhood: a report of two cases. SAJCH 2014; 8 (01) 39-40
- 10 Castillo JJ, Furman M, Beltrán BE. et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012; 118 (21) 5270-5277
- 11 Castillo JJ, Winer ES, Stachurski D. et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010; 51 (11) 2047-2053
- 12 Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant 2014; 20 (12) 1877-1884
- 13 NCCN. AIDS-Related B-Cell Lymphoma. 2021; National Comprehensive Cancer Network (NCCN) Guidelines. Accessed at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480 2024
- 14 Makady NF, Ramzy D, Ghaly R, Abdel-Malek RR, Shohdy KS. The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes. Clin Lymphoma Myeloma Leuk 2021; 21 (03) e255-e263
- 15 Chicuellar NR, Sufyan W, Mahendran S. Unilateral maxillary sinus plasmablastic lymphoma in an immunocompetent patient. An unusual occurrence report and literature review. Ear Nose Throat J 2022; 101 (06) NP251-NP255
- 16 DiBlasi M, Jayne C, McNamara R, Iasiello C, Colden D. Sinonasal plasmablastic lymphoma arising in the setting of recurrent nasal polyposis in an immunocompetent individual. Ear Nose Throat J 2024; 103 (09) 538-542
- 17 Lee KT, Misron NA, Abdul Aziz N, Wong CH, Liew HK. Spontaneous regression of plasmablastic lymphoma in an immunocompetent patient: case report and review of the literature. Case Rep Hematol 2022; 2022: 1142049
- 18 Rapiti N, Peer N, Abdelatif N, Rapiti P, Moosa Y. HIV-associated plasmablastic lymphoma: a single-centre 12-year experience in Kwa-Zulu Natal, South Africa. HIV Med 2022; 23 (08) 837-848
- 19 Sabry W, Wu Y, Kodad SG. Bortezomib, lenalidomide and dexamethasone combination induced complete remission in relapsed/refractory plasmablastic lymphoma: case report of a potential novel treatment approach. Curr Oncol 2022; 29 (07) 5042-5053
- 20 Cai J, Qiu L, Ma L, Zhang N, Fan FY. Case report: bortezomib plus CDOP followed by sequential autologous hematopoietic stem cell transplantation and lenalidomide-based maintenance therapy in plasmablastic lymphoma. Front Med (Lausanne) 2021; 8: 749863
- 21 Castillo JJ, Lamacchia J, Silver J, Flynn CA, Sarosiek S. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol 2021; 96 (10) E390-E392
- 22 Lasrado S, Naaz S, Moras K, D'Souza C, Loka SR. Analysis of disease patterns in patients with unilateral sinonasal diseases: a tertiary care hospital experience. Indian J Otolaryngol Head Neck Surg 2022; 74 (01) 63-69
- 23 Mariani R, King RL, Liu H. EBV-positive plasmacytomas involving a nasopharyngeal angiofibroma in an adolescent. Pediatr Dev Pathol 2021; 24 (03) 264-268
- 24 Modi N, Khurana U, Mukhopadhyay S. et al. An unusual case of paediatric plasmablastic lymphoma presenting with malignant effusion and the challenges in its diagnosis. Diagn Cytopathol 2021; 49 (10) E389-E394
- 25 Ando K, Imaizumi Y, Kobayashi Y. et al. Bortezomib- and lenalidomide-based treatment of refractory plasmablastic lymphoma. Oncol Res Treat 2020; 43 (03) 112-116
- 26 Furlan K, Miller I, Mahon B, Ocampo Gonzalez FA, Ward N. Plasmablastic lymphoma associated with adjacent mature plasma cell population exhibiting opposite light chain restriction. Case Rep Pathol 2020; 2020: 8875547
- 27 Li YJ, Li JW, Chen KL. et al. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res 2020; 55 (01) 49-56
- 28 He L, Li Z, Fan X, Shi Q, Wu H, Chen J. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients: a diagnostic dilemma. Int J Clin Exp Pathol 2020; 13 (03) 582-586
- 29 Mai B, Wang W, Lin M. et al. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. AIDS 2020; 34 (12) 1735-1743
- 30 Miao L, Guo N, Feng Y. et al. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology 2020; 76 (02) 201-211
- 31 Shakri NM, Husain S, Zahedi FD, Tan GC. Nasal plasmablastic lymphoma in an HIV-negative immunocompetent patient. Medeniyet Med J 2020; 35 (01) 71-74
- 32 Shwe S, Sharma AA, Lee BA, Smith JE. Relapse of plasmablastic lymphoma with cutaneous involvement in an immunocompetent male. Ear Nose Throat J 2022; 101 (05) NP222-NP225
- 33 Yap DRY, Tan GF, Chang EWY. et al. Clinical features of plasmablastic lymphoma: case series from an Asian tertiary cancer center and literature review. J Hematol (Brossard) 2020; 9 (03) 71-78
- 34 Perkins JN, Chi AW, Patel NJ. Plasmablastic lymphoma of the nasal septum. JAMA Otolaryngol Head Neck Surg 2019; 145 (09) 868-869
- 35 Rodrigues AI, Cabeçadas J, Martins Fernandes R, Viana Coelho M, Sousa C. Plasmablastic lymphoma of the maxillary sinus. Intern Emerg Med 2019; 14 (08) 1337-1338
- 36 Gibbs JD, Leon ME, Liu K, Nguyen J, Zhang L. A rare case of Epstein-Barr virus-related plasmacytoma involving maxillary sinus mucosa. Clin Case Rep 2017; 5 (09) 1482-1485
- 37 Rafei H, El-Bahesh E, Finianos A, Liu ML, Schechter GP. Plasmablastic lymphoma: case report of prolonged survival of an advanced human immunodeficiency patient and literature review. Case Rep Hematol 2017; 2017: 9561013
- 38 Wang D, Zheng Y, Zeng D. et al. Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. Int J STD AIDS 2017; 28 (04) 380-388
- 39 Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol 2017; 27: 1-6
- 40 Koizumi Y, Uehira T, Ota Y. et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol 2016; 104 (06) 669-681
- 41 Pinnix CC, Shah JJ, Chuang H. et al. Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review. Clin Lymphoma Myeloma Leuk 2016; 16 (03) 122-128
- 42 Segal N, Schneider S, Parra AS, Benharroch D. Case report: lymphoma in a nasopharyngeal branchial cleft cyst. B-ENT 2016; 12 (01) 67-71
- 43 Elyamany G, Alzahrani AM, Aljuboury M. et al. Clinicopathologic features of plasmablastic lymphoma: single-center series of 8 cases from Saudi Arabia. Diagn Pathol 2015; 10: 78
- 44 Loghavi S, Khoury JD, Medeiros LJ. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology 2015; 67 (02) 225-234
- 45 Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS. Proton therapy in the management of non-Hodgkin lymphoma. Leuk Lymphoma 2015; 56 (09) 2608-2612
- 46 Ambrosio MR, De Falco G, Gozzetti A. et al. Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. Haematologica 2014; 99 (11) e235-e237
- 47 Yasuhara R, Irié T, Shiozawa E. et al. Plasmablastic lymphoma of the maxillary sinus with intraoral manifestation caused by direct alveolar bone infiltration in an HIV-negative patient. Pathol Int 2014; 64 (11) 588-590
- 48 Saraceni C, Agostino N, Cornfield DB, Gupta R. Plasmablastic lymphoma of the maxillary sinus in an HIV-negative patient: a case report and literature review. Springerplus 2013; 2 (01) 142
- 49 Liu F, Asano N, Tatematsu A. et al. Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder. Histopathology 2012; 61 (06) 1183-1197
- 50 Liu JJ, Zhang L, Ayala E. et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res 2011; 35 (12) 1571-1577
- 51 Suzuki Y, Yoshida T, Nakamura N. et al. CD3- and CD4-positive plasmablastic lymphoma: a literature review of Japanese plasmablastic lymphoma cases. Intern Med 2010; 49 (16) 1801-1805
- 52 Kim JE, Kim YA, Kim WY. et al. Human immunodeficiency virus-negative plasmablastic lymphoma in Korea. Leuk Lymphoma 2009; 50 (04) 582-587
- 53 Morley AMS, Verity DH, Meligonis G, Rose GE. Orbital plasmablastic lymphoma–comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit. Orbit 2009; 28 (06) 425-429
- 54 Ustun C, Reid-Nicholson M, Nayak-Kapoor A. et al. Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. Ann Hematol 2009; 88 (04) 351-358
- 55 Chetty R, Hlatswayo N, Muc R, Sabaratnam R, Gatter K. Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. Histopathology 2003; 42 (06) 605-609
- 56 Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P. Plasmablastic lymphoma: cytologic findings in 5 cases with unusual presentation. Cancer 2008; 114 (05) 333-341
- 57 Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 2005; 29 (12) 1633-1641
- 58 Schichman SA, McClure R, Schaefer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol 2004; 77 (03) 291-295
- 59 Nguyen DD, Loo Jr BW, Tillman G. et al. Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report. Ann Hematol 2003; 82 (08) 521-525
- 60 Castillo JJ, Winer ES, Stachurski D. et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 2010; 15 (03) 293-299
- 61 Dodero A, Guidetti A, Tucci A. et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia 2019; 33 (04) 1047-1051
- 62 Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Survival analysis in treated plasmablastic lymphoma patients: a population-based study. Am J Hematol 2020; 95 (11) 1344-1351